project spending as well as capitalizing certain expenditures on the project versus expensing them as research and development cost.
Although new funding for this project was limited in 2012, the Company successfully completed the NRC licensing process by receiving the NRC combination construction and operating license in October 2012. The Company also reported successful completion of its Fluorine Extraction Process (FEP) test program during 2012 and the expected shutdown of the FEP pilot scale facility during 2013.
Cost of Revenue and Gross Profit Cost of revenue for 2012 was $4,970,033, as compared to $6,045,471 in 2011, a decrease of $1,075,438 or approximately 18%. Gross profit percentage decreased to 35% for 2012, from 36% in 2011. The slight decrease in gross profit can be attributed to incremental increases in the cost of manufacturing materials including increases in freight costs.
Operating Costs and ExpensesTotal operating costs and expenses for 2012 were $4,835,351, as compared to $6,786,991 in 2011; this is a decrease of
$1,951,640 or approximately 29%. Salaries and Contract Labor decreased 38% in 2012, as compared to 2011. Salaries and Contract Labor included approximately $286,000 in equity-based compensation in 2012, as compared to approximately $1,400,000 in 2011. This decrease was the result of recording a significant amount of non-cash, equity-based compensation expense in 2011 resulting from modification to the terms of several classes of warrants. General, Administrative and Consulting expenses decreased 4% to $1,946,105 in 2012, as compared to $2,031,862 in 2011. Research and development expense was $990,021 for 2012 as compared to $1,695,315 for 2011. This is a decrease of $705,294, or approximately 42%. The majority of research and development expense, reported in both 2012 and 2011, was incurred for planning and licensing activities with regard to the planned
Page: 1 2 3 4 5 6 7 8 Related medicine technology :1
|SOURCE International Isotopes Inc|
Copyright©2012 PR Newswire.
All rights reserved
. Max Neeman International Adds to Existing Six Sigma, SOP Training2
. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus3
. Kepner-Tregoe (KT) Announces 2012 International Process Achievement Award Recipients4
. Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash5
. Research-based Pharmaceutical Industry and International Federation of Red Cross and Red Crescent Societies Join Forces to Prevent Non-Communicable Diseases6
. PAREXEL International Provides Update On Share Repurchase Program, Announces A New $50 Million Accelerated Share Repurchase Agreement And A New $50 Million 10b5-1 Trading Plan7
. DMH International Selects Beta Partners for TouchPACS8
. HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock9
. HeartWare International, Inc. Announces Public Offering of Common Stock10
. The Societe Internationale dUrologie launches SIU Academy, a powerful new resource for urologists.11
. Mr. William Lerner, Esq. nominated to the Board of Directors of Sanomedics International Holdings, Inc.